



## Clinical trial results:

### A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Subjects With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer.

#### Summary

EudraCT number	2013-000698-57
Trial protocol	GB BE IT IE ES
Global end of trial date	

#### Results information

Result version number	v1
This version publication date	11 August 2018
First version publication date	11 August 2018

#### Trial information

##### Trial identification

Sponsor protocol code	MDV3100-11
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01889238
WHO universal trial number (UTN)	-
Other trial identifiers	Alias identifier: MDV3100-11

Notes:

#### Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer, Inc., Pfizer ClinicalTrials.gov Call Center, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 18007181021, ClinicalTrials.gov_inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	28 November 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 March 2015
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine the clinical benefit rate, defined as the proportion of evaluable subjects with androgen receptor positive (AR+) triple negative breast cancer (TNBC) with a best response of complete response (CR), partial response (PR), or stable disease greater than or equal ( $\geq$ ) 16 weeks

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 June 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	24 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Canada: 9
Country: Number of subjects enrolled	United Kingdom: 9
Country: Number of subjects enrolled	Ireland: 6
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	United States: 74
Worldwide total number of subjects	118
EEA total number of subjects	35

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	74
From 65 to 84 years	44
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted at 34 centres in 7 countries. Data reported based on primary analysis date (01 March 2015).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Enzalutamide
-----------	--------------

Arm description:

Subjects received enzalutamide 160 milligram (mg) (as four 40 mg soft gelatin capsules), orally once daily until disease progression (DP), intolerable adverse events (AEs) (including any seizures), noncompliance with protocol requirements, initiation of a new antitumor treatment, or subjectt or physician decision to discontinue treatment (up to a maximum of 87 Weeks).

Arm type	Experimental
Investigational medicinal product name	Enzalutamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Enzalutamide 160 mg was administered as four 40-mg soft gelatin capsules by mouth once daily.

Number of subjects in period 1	Enzalutamide
Started	118
Completed	109
Not completed	9
Treatment ongoing	9

## Baseline characteristics

### Reporting groups

Reporting group title	Enzalutamide
-----------------------	--------------

Reporting group description:

Subjects received enzalutamide 160 milligram (mg) (as four 40 mg soft gelatin capsules), orally once daily until disease progression (DP), intolerable adverse events (AEs) (including any seizures), noncompliance with protocol requirements, initiation of a new antitumor treatment, or subjectt or physician decision to discontinue treatment (up to a maximum of 87 Weeks).

Reporting group values	Enzalutamide	Total	
Number of subjects	118	118	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	74	74	
From 65-84 years	44	44	
85 years and over	0	0	
Age Continuous			
Age Continuous is provided for treated subjects only			
Units: years			
arithmetic mean	58.3		
standard deviation	± 12.95	-	
Sex: Female, Male			
Units: Subjects			
Female	118	118	
Male	0	0	

## End points

### End points reporting groups

Reporting group title	Enzalutamide
Reporting group description:	
Subjects received enzalutamide 160 milligram (mg) (as four 40 mg soft gelatin capsules), orally once daily until disease progression (DP), intolerable adverse events (AEs) (including any seizures), noncompliance with protocol requirements, initiation of a new antitumor treatment, or subjectt or physician decision to discontinue treatment (up to a maximum of 87 Weeks).	

### Primary: Percentage of Subjects With Clinical Benefit (CB) at Week 16: Evaluable Population

End point title	Percentage of Subjects With Clinical Benefit (CB) at Week 16: Evaluable Population <sup>[1]</sup>
-----------------	---

End point description:

CB at Week 16: best response of complete response (CR), partial response (PR), stable disease (SD) for  $\geq 16$  weeks on radiologic imaging per Investigator using RECIST 1.1. Estimate of percentage, its exact 2-sided 85% confidence interval were calculated by Blaker method. CR: disappearance of all target, non-target lesions, normalization of tumor marker level, all lymph nodes decreased to non-pathological in size  $< 10$  mm short axis. PR:  $\geq 30\%$  decrease in sum of longest diameter (LD) of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using smallest sum diameters during study as a reference. Evaluable population: enrolled subjects with centrally assessed AR + breast cancer (total nuclear AR expression in  $\geq 10\%$  of tumor cells), had at least 1 dose of study drug with  $\geq 1$  available post baseline tumor assessment per RECIST 1.1.

End point type	Primary
----------------	---------

End point timeframe:

Week 16

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for the endpoint

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: percentage of subjects				
number (confidence interval 85%)	33.3 (25.53 to 41.63)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Clinical Benefit (CB) at Week 16: Intent-to-Treat (ITT) Population

End point title	Percentage of Subjects With Clinical Benefit (CB) at Week 16: Intent-to-Treat (ITT) Population <sup>[2]</sup>
-----------------	---

End point description:

Clinical benefit at Week 16 defined as percentage of subjects with a best response of CR, PR, or SD for

$\geq 16$  weeks on radiologic imaging based on Investigator assessment using RECIST 1.1. An estimate of % and its exact 2-sided 85% CI were calculated using Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size  $<10$  mm short axis. PR:  $\geq 30\%$  decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using smallest sum diameters during study as a reference. ITT population included all enrolled participants who had centrally assessed AR+ breast cancer and received at least 1 dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 16

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for the endpoint

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: percentage of subjects				
number (confidence interval 85%)	24.6 (18.98 to 30.88)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Clinical Benefit at Week 24: Evaluable Population

End point title	Percentage of Subjects With Clinical Benefit at Week 24: Evaluable Population
-----------------	---

End point description:

Percentage of subjects with a clinical benefit at Week 24 defined as percentage of subjects with a best response of CR, PR, or SD for  $\geq 24$  weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size  $<10$  mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference. Evaluable population set was used in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: percentage of subjects				
number (confidence interval 85%)	28.2 (21.04 to 36.48)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Clinical Benefit at Week 24: ITT Population

End point title	Percentage of Subjects With Clinical Benefit at Week 24: ITT Population
-----------------	---

End point description:

Clinical benefit at Week 24 defined as percentage of subjects with a best response of CR, PR, or SD for  $\geq 24$  weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size  $<10$  mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference. ITT population set was used in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: percentage of subjects				
number (confidence interval 85%)	20.3 (15.16 to 26.21)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Best Objective Response: Evaluable Population

End point title	Percentage of Subjects With Best Objective Response: Evaluable Population
-----------------	---

End point description:

Percentage of subjects with best objective response defined as percentage of subjects with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in  $<10$  mm



short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. Analysis was performed on subjects from Evaluable population who had measurable disease.

End point type	Secondary
End point timeframe:	
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)	

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	59			
Units: percentage of subjects				
number (confidence interval 85%)	8.5 (3.05 to 12.02)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Best Objective Response: ITT Population

End point title	Percentage of Subjects With Best Objective Response: ITT Population
-----------------	---

End point description:

Percentage of subjects with best objective response defined as percentage of subjects with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in <10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. Analysis was performed on subjects from ITT population who had measurable disease.

End point type	Secondary
End point timeframe:	
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)	

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: percentage of subjects				
number (confidence interval 85%)	6.2 (2.80 to 8.95)			

### Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-Free Survival (PFS): Evaluable Population

End point title	Progression-Free Survival (PFS): Evaluable Population
-----------------	---

End point description:

PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as:  $\geq 20$  percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. Evaluable population included all enrolled subjects who had centrally assessed AR + breast cancer (total nuclear AR expression in  $\geq 10\%$  of tumor cells), had at least 1 dose of study drug and had at least 1 available post baseline tumor assessment evaluable as per RECIST 1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: weeks				
median (confidence interval 85%)	14.3 (8.3 to 16.1)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-Free Survival: ITT Population

End point title	Progression-Free Survival: ITT Population
-----------------	---

End point description:

PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as:  $\geq 20$  percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. ITT population included all enrolled subjects who had centrally assessed AR+ breast cancer and received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: weeks				
median (confidence interval 85%)	12.6 (8.1 to 15.1)			

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Trough Plasma Concentration of Enzalutamide and its Metabolite

End point title	Trough Plasma Concentration of Enzalutamide and its Metabolite
-----------------	--

End point description:

M2 was the metabolite of enzalutamide. The lower limit of quantitation (LLQ) was 0.0200 micrograms per milliliter (mcg/ml) for enzalutamide and M2. Pharmacokinetics (PK) analysis population included all subjects who received 1 dose or partial dose of study drug, and who had at least 1 enzalutamide or M2 plasma concentration assessment. Here, "99999" signifies that none of the subjects had data above LLQ and as per the predefined protocol, values below the limit of quantitation (BLQ) were set to missing and hence not reported.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Predose on Day 1 (Baseline), Week 9 and Week 17

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	115			
Units: mcg/ml				
geometric mean (geometric coefficient of variation)				
Enzalutamide Day 1	99999 (± 99999)			
M2 Day 1	99999 (± 99999)			
Enzalutamide Week 9	12.59 (± 33.46)			
M2 Week 9	13.48 (± 35.64)			
Enzalutamide Week 17	12.79 (± 37.33)			
M2 Week 17	13.88 (± 25.47)			

## Statistical analyses

No statistical analyses for this end point

---

**Other pre-specified: Number of Subjects with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)**

---

End point title	Number of Subjects with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
-----------------	---

End point description:

An AEs was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was an AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events between first dose of study drug and up to 87 weeks that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs. Safety population included all subjects who received 1 dose or partial dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to 87 weeks

---

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: subjects				
Adverse Events	109			
Serious Adverse Events	29			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Other pre-specified: Number of Subjects With Study Drug Discontinuation due to Adverse Events**

---

End point title	Number of Subjects With Study Drug Discontinuation due to Adverse Events
-----------------	--

End point description:

Safety population included all subjects who received 1 dose or partial dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to 87 weeks

---

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: subjects	8			

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Number of Subjects With Grade 3 or Higher Adverse Events

End point title	Number of Subjects With Grade 3 or Higher Adverse Events
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. As per the NCI CTCAE, version 4.0, Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death. Only the subjects with treatment-emergent AEs of Grade 3 (severe) or higher grade were reported in this endpoint. Safety population included all subjects who received 1 dose or partial dose of study drug

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to 87 weeks

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: subjects	36			

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Number of Subjects With Clinically Significant Change From Baseline in Vital Signs

End point title	Number of Subjects With Clinically Significant Change From Baseline in Vital Signs
-----------------	--

End point description:

Criteria: Systolic blood pressure (SBP): absolute SBP<90 millimeters of mercury (mmHg) and decrease from baseline (DFB)>30mmHg, absolute SBP>180mmHg and increase from baseline (IFB)>40 mmHg, final visit or 2 consecutive visits SBP>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP>=140mmHg, most extreme post-baseline SBP>=180mmHg, most extreme SBP>=140mmHg and>=20 mmHg CFB, most extreme SBP>=180mmHg and>=20mmHg CFB; diastolic blood pressure (DBP): absolute DBP>105mmHg and IFB>30mmHg, absolute DBP<50mmHg and DFB>20mmHg, final visit or 2 consecutive visits DBP>=15mmHg CFB, most extreme post-baseline DBP>=90mmHg, most extreme post-baseline DBP>=105mmHg, most extreme DBP>=90mmHg and>=15mmHg CFB, most extreme DBP>=105mmHg and>=15mmHg CFB; heart rate<50beats per minute (BPM) and DFB>20BPM or heart rate>120BPM and IFB>30BPM. Only those categories, in which at least 1 subject had data were reported. Safety population set was used in the analysis.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:  
Baseline up to 87 weeks

End point values	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: subjects				
SBP: absolute SBP <90 mmHg and DFB>30 mmHg	1			
SBP: FV or 2 CV SBP>=20 mmHg CFB	9			
SBP: Most extreme post baseline SBP >=140 mmHg	36			
SBP: Most extreme post baseline SBP >=180 mmHg	1			
SBP:Most extreme SBP>=140 mmHg and>=20 mmHg CFB	11			
DBP: FV or 2 CV DBP>=15 mmHg CFB	10			
DBP: Most extreme post baseline result >=90 mmHg	22			
DBP: Most extreme post baseline result >=105 mmHg	4			
DBP:Most extreme DBP>=105 mmHg and>=15 mmHg CFB	2			
DBP:Most extreme DBP>=90 mmHg and>=15 mmHg CFB	12			

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Number of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades

End point title	Number of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades
-----------------	--

End point description:

Laboratory tests included hematology parameters (low lymphocytes, WBC, neutrophils, hemoglobin and platelets) and chemistry parameters (mean albumin, Blood urea nitrogen [BUN], calcium, Lactate dehydrogenase [LDH], alanine aminotransferase, Aspartate aminotransferase, bilirubin, Alkaline phosphatase, creatinine and glucose). Number of participants with change from baseline in laboratory parameters Grades by 2 or More Grades as per National Cancer Institute Common Terminology Criteria (NCI CTC) (Grade 0= within normal limits, Grade 1=Mild, Grade 2=Moderate, Grade 3= Severe, Grade 4= Life-threatening) were reported. Safety population included all participants who receive 1 dose or partial dose of study drug.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline up to 87 weeks

<b>End point values</b>	Enzalutamide			
Subject group type	Reporting group			
Number of subjects analysed	118			
Units: subjects				
Hemoglobin	1			
Leukocytes	4			
Lymphocytes	12			
Neutrophils	2			
Platelets	1			
Alanine aminotransferase	1			
Albumin	4			
Alkaline phosphatase	3			
Bilirubin	2			
Calcium	2			
Glucose	5			
Phosphate	4			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to 87 weeks

Adverse event reporting additional description:

Same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject or one subject may have experienced both a serious and non-serious event during the study. AEs and SAEs were collected for safety population.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Enzalutamide
-----------------------	--------------

Reporting group description:

Subjects received enzalutamide 160 mg (as four 40 mg soft gelatin capsules), orally once daily until disease progression, intolerable AEs (including any seizures), noncompliance with protocol requirements, initiation of a new antitumor treatment, or subject or physician decision to discontinue treatment (up to a maximum of 87 Weeks).

Serious adverse events	Enzalutamide		
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 118 (24.58%)		
number of deaths (all causes)	12		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastatic pain			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Malignant pleural effusion			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Breast cancer metastatic			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		



Pericardial effusion malignant subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Invasive ductal breast carcinoma subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm progression subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Metastases to central nervous system subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases to lung subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Hip fracture subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Radiation oesophagitis subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Toxicity to various agents subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 118 (0.85%) 0 / 1 0 / 0		
Traumatic fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 118 (0.85%) 0 / 1 0 / 0		
Cardiac disorders Pericardial effusion subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 118 (1.69%) 0 / 2 0 / 2		
Myocardial infarction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 118 (0.85%) 0 / 1 0 / 0		
Nervous system disorders Spinal cord compression subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 118 (1.69%) 0 / 2 0 / 0		
Cognitive disorder subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 118 (0.85%) 0 / 1 0 / 0		
General disorders and administration site conditions Disease progression subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	3 / 118 (2.54%) 0 / 3 0 / 3		
General physical health deterioration			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pain			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	3 / 118 (2.54%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 2		
Pleuritic pain			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Musculoskeletal chest pain			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pathological fracture			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Lung infection			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	2 / 118 (1.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Cellulitis			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Device related infection			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			

subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Soft tissue infection			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	1 / 118 (0.85%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Enzalutamide		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	100 / 118 (84.75%)		
Investigations			
Weight decrease			
subjects affected / exposed	8 / 118 (6.78%)		
occurrences (all)	11		
Vascular disorders			
Hot flush			
subjects affected / exposed	12 / 118 (10.17%)		
occurrences (all)	13		
Nervous system disorders			
Headache			
subjects affected / exposed	17 / 118 (14.41%)		
occurrences (all)	17		
Dizziness			

subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 9		
Neuropathy peripheral subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 6		
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	49 / 118 (41.53%) 64		
Pain subjects affected / exposed occurrences (all)	9 / 118 (7.63%) 9		
Asthenia subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 8		
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	40 / 118 (33.90%) 51		
Diarrhoea subjects affected / exposed occurrences (all)	18 / 118 (15.25%) 22		
Constipation subjects affected / exposed occurrences (all)	18 / 118 (15.25%) 18		
Vomiting subjects affected / exposed occurrences (all)	11 / 118 (9.32%) 14		
Abdominal pain subjects affected / exposed occurrences (all)	7 / 118 (5.93%) 7		
Reproductive system and breast disorders			
Breast Pain subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 6		
Respiratory, thoracic and mediastinal			

disorders			
Dyspnoea			
subjects affected / exposed	13 / 118 (11.02%)		
occurrences (all)	15		
Cough			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	7		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	17 / 118 (14.41%)		
occurrences (all)	17		
Anxiety			
subjects affected / exposed	7 / 118 (5.93%)		
occurrences (all)	10		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	17 / 118 (14.41%)		
occurrences (all)	23		
Arthralgia			
subjects affected / exposed	17 / 118 (14.41%)		
occurrences (all)	19		
Pain in extremity			
subjects affected / exposed	9 / 118 (7.63%)		
occurrences (all)	16		
Musculoskeletal pain			
subjects affected / exposed	10 / 118 (8.47%)		
occurrences (all)	10		
Muscle spasms			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	7		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	6 / 118 (5.08%)		
occurrences (all)	6		
Upper respiratory tract infection			

subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 6		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	22 / 118 (18.64%) 23		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 October 2013	1- Modified to require head imaging using magnetic resonance imaging (MRI) with contrast to rule out central nervous system (CNS) metastatic disease; head computed tomography (CT) with contrast could be considered after discussion with the medical monitor. Instructions for head imaging were provided for subjects enrolled before this amendment. 2- Increased the sample size from 80 to 95 subjects to ensure an adequate number of evaluable subjects for the primary and secondary efficacy endpoint analyses. 3- Modified exclusion criterion 10 to remove the option of using a creatinine clearance estimation by Cockcroft Gault. Renal function was to be assessed using a single parameter (serum creatinine) to enable analysis by common terminology criteria for adverse events (CTCAE) severity grading. 4- Clarified that modalities other than radiographic methods (such as physical examination) could be used for disease status assessments per RECIST 1.1; positron emission tomography (PET) imaging was not to be used. 5- Clarified that the primary efficacy endpoint of clinical benefit rate at 16 weeks was to be based on investigator determination of response using RECIST 1.1. 6- Provided guidance for late doses and updated the directions for dose modification. 7- Added instructions for reporting pregnancies. 8- Removed requirements for reporting certain adverse events as serious.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As per change in planned analysis, AR low population (all enrolled subjects who had AR nuclear staining > 0%, < 10% assessed centrally) was not analyzed for efficacy and duration of response, time to response were not analyzed for any population

Notes: